Plenary Keynote Session

The Next 10 Years: Looking Ahead to Next-Gen Bioprocessing

Wednesday, August 15 (4:45 - 6:25pm)

4:45 pm Chairperson’s Remarks

John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News (GEN)


Murray_Jerry4:50 Digital Transformation to Advance Next-Generation Biomanufacturing through Data Integration and Analytics

Jerry Murry, PhD, Senior Vice President, Process Development, Amgen

Hundreds of millions of data points are currently generated through the development and execution of biopharmaceutical processes. It is expected that the volume and complexity of biomanufacturing data is set to grow exponentially as developers and manufacturers integrate novel sensors, smart materials, process analytical technologies and process automation into laboratories and manufacturing plants. This presentation will describe the value associated with a comprehensive digital strategy incorporating a structured data integration and analytics platform inclusive of AI, predictive modeling and visualization, and how digital transformation can advance next-generation biomanufacturing.

5:20 Driving Change in Biomanufacturing through Innovation in Processes, Technologies and Operations

Eliana Clark, PhD, Vice President, International Manufacturing Operations, Biogen

A critical step in meeting the demand of biologic production worldwide involves implementing disruptive manufacturing technologies, processes and capabilities. This talk will use Biogen’s new manufacturing site in Switzerland, due to go online in 2019, as an example to demonstrate the new processes, operational models and technologies being adopted to drive value through innovation and deliver new medicines in areas such as Alzheimer’s.

5:50 End-to-End Solutions Considering New Trends in Biomanufacturing

Guillaume Plane, MSc, MBA, Manager, Global Development, Biodevelopment Solutions, MilliporeSigma

The presentation will get into the current state of biomanufacturing, from DNA to market approval, considering the way a key supplier can support drug makers to the fullest, thanks to a deep understanding of the trends that could affect our industry in the midterm, including growth of the pipelines, strengthening of regulations, and acceleration of timelines, for development as well as for the set-up of capabilities. Some thoughts and ideas will be proposed to consider commercial manufacturing with single-use equipment.

6:25 Close of Plenary Keynote Session

Plenary Keynote Speaker Biographies

Jerry Murry, PhD, Senior Vice President, Process Development, Amgen

Over the past 12 years, Jerry has demonstrated the ability to lead critically important efforts for R&D, Operations and Amgen overall. Jerry has held several roles including: vice president, Small Molecule Process & Product Development, vice president, Chemistry, Manufacturing & Controls Lifecycle Management and most recently as vice president, Drug Product Technologies.

Jerry received his bachelor’s degree in biochemistry from Texas Lutheran University and his Ph.D. degree in chemistry from the University of Utah. Jerry was a National Institutes of Health (NIH) fellow at Harvard University before joining Pfizer Central Research in 1994. In 2000, Jerry joined Merck Research Laboratories where he held positions of increasing responsibility.


Eliana Clark, PhD, Vice President, International Manufacturing Operations, Biogen 

Eliana Clark is Vice President of Global Manufacturing Sciences at Biogen. In this role, she leads the global network accountable for providing scientific and technical support for all process related aspects of clinical and commercial manufacturing of large and small molecules, and end to end manufacturing from raw materials to finished goods. Prior to her role as the leader of the Global Manufacturing Sciences organization, Eliana was the operations asset leader for Zynbrita, Biogen’s recently approved Multiple Sclerosis drug. Prior to Biogen, Eliana held positions of increasing responsibility at Genzyme, a Sanofi Company, where she led the Late Stage Drug Product Development organization, the Manufacturing Sciences and Technology group supporting both Drug Substance and Drug Product manufacturing at the Allston Landing Facility, and the CMC regulatory group, supporting US manufacturing sites for Genzyme. Prior to Genzyme, Eliana was a professor and a leader at Tufts University. During her tenure at Tufts, Eliana was the Assistant Director of the Biotechnology Center and the Chair of the Chemical and Biological Engineering Department. Eliana holds a Ph.D. in Chemical Engineering with post doctorates from the University of Delaware and Worcester Polytechnic Institute.


Guillaume Plane, MSc, MBA, Manager, Global Development, Biodevelopment Solutions, MilliporeSigma 

Guillaume Plane is a Global Development and Marketing Manager for MilliporeSigma’s Biodevelopment Solutions department.  Guillaume joined MilliporeSigma in 2012, bringing over 15 years of biotechnology experience spanning multiple specialties, including biochemistry, molecular biology and biomanufacturing. He also serves as Visiting Professor at Sup’Biotech Engineering School, after he served at ESCP Europe, ESC Toulouse, and IONIS School of Technology and Management.

Guillaume began his career as a Research Fellow with the University of Bordeaux, and later served as Business Developer with the Aventis Foundation. Guillaume went on to become an entrepreneur as a Founder of MitoProd SA over seven years, a biotechnology company devoted to the biomanufacturing of RNA.

Guillaume received a master’s degree in Biology and Health from the University of Bordeaux, and an additional master’s degree in Innovation and Entrepreneurship from ESCP Europe.

Premier Sponsors:

Register Today!